ABBV-CLS-628 is currently being evaluated in a phase 2 trial in an estimated 240 adults with ADPKD class 1C, 1D, or 1E. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

A fast-track kidney transplant evaluation approach increased the likelihood of waitlist placement by 40%. Patients in the fast-track group had a 21% higher likelihood of receiving a kidney transplant ...

Calico Life Sciences announced on Thursday that the U.S. Food and Drug Administration (FDA) has issued Fast Track Designation for ABBV-CLS-628, a kidney disease therapy developed by the company in ...

A kidney transplant fast track program improved waitlisting and kidney transplantation rates compared with standard care, and especially reduced disparities for Black patients. A kidney transplant ...

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2025 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and ...